Are Consumer Staples Stocks Lagging Freshpet (FRPT) This Year?
https://www.zacks.com/stock/news/2242143/are-consumer-staples-stocks-lagging-freshpet-frpt-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2242143
Mar 18, 2024 - Here is how Freshpet (FRPT) and Post Holdings (POST) have performed compared to their sector so far this year.
0
Is Post Holdings (POST) Stock Undervalued Right Now?
https://www.zacks.com/stock/news/2242105/is-post-holdings-post-stock-undervalued-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2242105
Mar 18, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
0
Clorox's (CLX) IGNITE Strategy to Evolve Portfolio Bodes Well
https://www.zacks.com/stock/news/2245096/clorox-s-clx-ignite-strategy-to-evolve-portfolio-bodes-well?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2245096
Mar 22, 2024 - Clorox (CLX) benefits from pricing actions and cost-saving initiatives. The company is on track to streamline its operating model to improve efficiency.
0
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
https://www.zacks.com/stock/news/2246921/moderna-mrna-posts-upbeat-data-from-next-gen-covid-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246921
Mar 27, 2024 - Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
0
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2246697/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2246697
Mar 27, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Post Holdings (POST) Gains on Effective Pricing & Acquisitions
https://www.zacks.com/stock/news/2248661/post-holdings-post-gains-on-effective-pricing-acquisitions?cid=CS-ZC-FT-analyst_blog|rank_focused-2248661
Apr 01, 2024 - Post Holdings (POST) intends to strengthen its business on the back of strategic acquisitions. The company is reaping benefits from a favorable pricing environment.
0
Acuity Brands (AYI) to Post Q2 Earnings: Factors to Consider
https://www.zacks.com/stock/news/2248480/acuity-brands-ayi-to-post-q2-earnings-factors-to-consider?cid=CS-ZC-FT-analyst_blog|earnings_preview-2248480
Apr 01, 2024 - Acuity Brands' (AYI) fiscal second-quarter performance is likely to have ailed from softness in the ABL segment amid cost improvement.
0
Airline Stock Roundup: AZUL Posts Loss in Q4, ALGT's February Traffic Improves
https://www.zacks.com/stock/news/2250435/airline-stock-roundup-azul-posts-loss-in-q4-algt-s-february-traffic-improves?cid=CS-ZC-FT-analyst_blog|stock_roundup-2250435
Apr 04, 2024 - JetBlue (JBLU) expands its international presence. Alaska Air (ALK) expects its long-term profitability to be hurt due to Boeing's woes.
0
Fastenal (FAST) to Post Q1 Earnings: What's in the Cards?
https://www.zacks.com/stock/news/2252013/fastenal-fast-to-post-q1-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2252013
Apr 08, 2024 - Fastenal's (FAST) Q1 results are likely to reflect manufacturing growth, albeit at a slow pace, with a strong digital strategy and a balanced onsite/offsite mix. Yet, slowing industrial markets are a concern.
0
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
https://www.zacks.com/stock/news/2253877/alx-oncology-alxo-posts-upbeat-results-from-lymphoma-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253877
Apr 11, 2024 - ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
0